Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors

Biochemical Pharmacology

Volumn 75, Issue 5, 2008, Pages 1186-1197

  Li, Cheng ^a   Nair, Latha ^a   Liu, Tongtong ^a   Li, Fangbiao ^a   Pichardo, John ^a   Agrawal, Sony ^a   Chase, Robert ^a   Tong, Xiao ^a   Uss, Annette S ^a   Bogen, Stephane ^a   Njoroge, F George ^a   Morrison, Richard A ^a   Cheng, K C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Caco 2 permeability; Cell uptake; Cell based activity; HCV protease inhibitor; PAMPA assay; Physico chemical property

Indexed keywords

PROTEINASE INHIBITOR;

ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; REPLICON;

CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DIFFUSION; HEPACIVIRUS; HUMANS; MEMBRANES, ARTIFICIAL; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 39149138103     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.10.031     Document Type: Article

References (29)

1. Li C., Wainhaus S., Uss A.S., and Cheng K.-C. High-throughput screening using Caco-2 and PAMPA systems. In: Kim K.-J., and Ehrhardt C. (Eds). Preclinical biopharmaceutics-in situ, in vitro, and in silico tools for drug absorption studies (2007), Springer 418-429
2. Balimane P.V., Chong S., and Morrison R.A. Current methodologies used for evaluation of intestinal permeability and absorption. J Phamacol Toxicol Methods 44 (2000) 301-312
3. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 8 (1991) 305-330
4. Chong S., Dando S., Soucek K., and Morrison R.A. In vitro permeability through caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 13 (1996) 120-123
5. Kansy M., Senner F., and Gubermator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41 (1998) 1007-1010
6. Avdeef A., Strafford M., Block E., Balogh M.P., Chabliss W., and Khan I. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci 14 (2001) 271-280
7. Avdeef A. Absorption and drug development (2003), Wiley-Interscience, New York, NY p. 116-246
8. Chong S., Dando S., and Morrison R.A. Evaluation of Biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 14 (1997) 1835-1837
9. Rubas W., Jezyk N., and Grass G.M. Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption. Pharm Res 10 (1993) 113-118
10. Reed K.E., and Rice C.M. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242 (2000) 55-84
11. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
12. Cheng K.-C., Korfmacher W.A., White R.E., and Njoroge F.G. Lead optimization in discovery drug metabolism and pharmacokinetics: case study-the hepatitis C virus protease inhibitor SCH 503034. Perspect Med Chem 1 (2007) 1-9
13. Liu R., Abid K., Pichardo J., Pazienza V., Ingravallo P., Kong R., et al. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. J Antimicrob Chemother 10 (2006) 1093-1098
14. Chen K.X., Njoroge F.G., Arasappan A., Venkatraman S., Vibulbhan B., Yang W., et al. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles. J Med Chem 49 (2006) 995-1005
15. Bogen S.L., Arasappan A., Bennett F., Chen K., Jao E., Liu Y.-T., et al. Discovery of SCH6: a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J Med Chem 49 (2006) 2750-2757
16. Venkatraman S., Bogen S.L., Arasappan A., Bennet F., Chen K., Jao E., et al. Discovery of SCH 503034, a selective potent, orally bioavailable HCV NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 49 (2006) 6074-6086
17. Burton P.S., Conradi R.A., Ho N.F.H., Hilgers A.R., and Borchardt R.T. How structural features influence the biomembrane permeability of peptides. J Pharm Sci 85 (1996) 1336-1340
18. Knipp G.T., Vander Velde D.G., Siahaan T.J., and Borchardt R.T. The effect of β-turn structure on the passive diffusion of peptides across Caco-2 cell monolayers. Pharm Res 14 (1997) 1332-1340
19. Adachi Y., Suzuki H., and Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18 (2001) 1660-1668
20. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27 (2006) 17-24
21. Ottaviani G., Martel S., and Carrupt P.-A. Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. J Med Chem 49 (2006) 3948-3954
22. Loftsson T., Konradsdottir F., and Masson M. Development and evaluation of an artificial membrane for determination of drug availability. Int J Pharm 326 (2006) 60-68
23. Fischer H., Kansy M., Avdeef A., and Senner F. Permeability of permanently positive charged molecules through artificial membranes-influence of physico-chemical properties. Eur J Pharm Sci 31 (2007) 32-42
24. Galinis-Luciani D., Nguyen L., and Yazdanian M. Is PAMPA a useful tool for discovery. J Pharm Sci 96 (2007) 2886-2892
25. Avdeef A., Bendels S., Di L., Faller B., Kansy M., Sugano K., et al. PAMPA-critical factors for better prediction of absorption. J Pharm Sci 96 (2007) 2893-2909
26. Rassetto L.A., Poon S., Tsourounis C., Valera C., and Benet L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther 81 (2007) 828-832
27. Lau Y.Y., Huang Y., Frassetto L., and Benet L.Z. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81 (2007) 194-204
28. Lu C., Li P., Gallegos R., Uttamsingh V., Xia C.Q., Miwa G.T., et al. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34 (2006) 1600-1605
29. Gangmar S., Jois S.D.S., Siahaan T.J., Vander Velde D.G., Stella V.J., and Borchardt R.T. The effect of conformation on membrane permeability of an acyloxlalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm Res 13 (1996) 1657-1662